Find a Clinical Trial
Filter
Collagen Urine Assay
Male
50-80
Recruiting now
Department of Urology
OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer (OPERA-01)
Breast cancer, Locally advanced and metastatic breast cancer
All genders
18+
Recruiting now
Cancer Center
R3R
Chronic kidney disease
All genders
12+
Recruiting now
Department of Medicine, Division of Nephrology
Treatment Combination of Durvalumab, Tremelimumab and Enfortumab Vedotin or Durvalumab and Enfortumab Vedotin in Patients With Muscle Invasive Bladder Cancer Ineligible to Cisplatin or Who Refuse Cisplatin (VOLGA)
Bladder cancer
All genders
18+
Recruiting now
Department of Medicine, Cancer Center
LYS228 Pharmacokinetics for Complicated UTI
Urinary tract infections
All genders
18-85
Recruiting now
Department of Urology
A Study of Dato-DXd Versus Investigator's Choice Chemotherapy
All genders
18+
Recruiting now
Department of Medicine, Division of Hematology/Oncology, Cancer Center
VX19-NEN-801
Chronic kidney disease, Glomerular disease, Kidney diseases, Proteinuria
All genders
12-65
Recruiting now
Department of Medicine, Division of Nephrology
Breast Cancer Database
Breast cancer
All genders
18+
Recruiting now
Department of Medicine, Division of Hematology/Oncology, Cancer Center
A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy (CAMBRIA-1)
All genders
18+
Recruiting now
Cancer Center
An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2)
Breast cancer
All genders
18+
Recruiting now
Cancer Center